ArticleAIDS (London, England)2026
Higher plasma kynurenine-tryptophan ratio predicts incident hepatic fibrosis in women with HIV.
Article in AIDS (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
objectiveChronic immune activation and microbial translocation may contribute to hepatic fibrosis in people with HIV. We evaluated whether plasma kynurenine-to-tryptophan (KT) ratio and other biomarkers of microbial translocation predict incident fibrosis in women with HIV.
designLongitudinal cohort study of 709 women with HIV from the Women's Interagency HIV Study with baseline plasma biomarkers and serial vibration-controlled transient elastography. Participants with baseline fibrosis or viral hepatitis were excluded. Outcomes included incident fibrosis, steatotic liver disease (SLD)-associated fibrosis, non-SLD fibrosis, and advanced fibrosis.
methodsPoisson regression with robust standard errors clustered by participant was used to estimate incidence rate ratios (IRRs) for liver outcomes by log-transformed KT ratio, adjusted for demographic, metabolic, and HIV-related covariates. Models included an offset for follow-up time. Analyses were repeated for sCD163, sCD14, and I-FABP.
resultsOver a mean follow-up of 42 months, 18.7% developed incident fibrosis, of whom 74% had SLD; 8.3% developed advanced fibrosis. In adjusted models, each log-unit increase in KT ratio was associated with incident fibrosis (IRR 1.46, 95% CI 1.21-1.76) and advanced fibrosis (IRR 1.59, 95% CI 1.27-1.99). KT ratio was associated with non-SLD fibrosis (IRR 1.59, 95% CI 1.31-1.94), but not SLD-associated fibrosis (IRR 1.16, 95% CI 0.94-1.42). Higher sCD163 was associated with all liver outcomes, whereas sCD14 and I-FABP were not.
conclusionsHigher KT ratio independently predicted incident hepatic fibrosis in women with HIV, particularly non-SLD fibrosis, suggesting a steatosis-independent pathway involving microbial translocation and macrophage activation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.